Recently, CKD outcome studies have established that cystatin C and albuminuria can improve risk stratification among persons with CKD defined by eGFRcr, with respect to mortality risk, cardiovascular disease, heart failure, and end stage renal disease [22, 42–44]. Here, CST3 is linked to cardiovascular disorder.